Aedifica gives an update on the approval of the Belgian competitive authorities in regards to the Cofinimmo merger. The Belgian authorities have asked additional information which might delay the timeline of the transaction. As a reminder the acceptance period was to open in September with the EGM to vote on a merger in October (depending on the 51.0% thresholds during the acceptance period). The Dutch/German authorities have already give approval. There is no further information on what details...
Aedifica NV/SA – Update on the progress of Aedifica’s and Cofinimmo’s case with the Belgian Competition Authority More information is available on Aedifica’s website via the link below and can be accessed subject to the usual restrictions.
Pharvaris has accelerated its timeline for topline data from the RAPIDe-3 Phase 3 trial evaluating deucrictibant for on-demand treatment of hereditary angioedema (HAE), now expected in 4Q25 instead of 1Q26. The study aims to confirm earlier Phase 2 findings and measures time to symptom relief. Pending positive results, Pharvaris plans to submit its FDA application in the first half of 2026. Meanwhile, the company is also advancing its prophylactic HAE program and planning studies in acquired ang...
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated...
Aedifica NV/SA: Publication relating to a transparency notification Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding a publication relating to a transparency notification. Attachments
MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.